Literature DB >> 27152512

Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting.

Rudolph M Navari1,2, Cindy K Nagy3, Jennifer Le-Rademacher4, Charles L Loprinzi4.   

Abstract

BACKGROUND: Concurrent chemotherapy radiation therapy may result in significant nausea and vomiting. There have been few studies reporting effective interventions for preventing treatment-related nausea and vomiting.
OBJECTIVE: To compare olanzapine with fosaprepitant for the prevention of nausea and vomiting in patients receiving concurrent highly emetogenic chemotherapy (HEC) and radiotherapy for locally advanced head and neck or esophageal cancer.
METHODS: 120 chemotherapy and radiotherapy naïve patients with head and neck cancer who were receiving concurrent local radiation and cisplatin were randomized to receive either olanzapine or fosaprepitant in combination with palonosetron and dexamethasone for the prevention of chemotherapy- and radiation-induced nausea and vomiting. The olanzapine, palonosetron, dexamethasone (OPD) regimen was 10 mg oral olanzapine , 0.25 mg IV palonosetron, and 20 mg IV dexamethasone before chemotherapy on day 1, and 10 mg/day of oral olanzapine before chemotherapy on days 2-4. The fosaprepitant, palonosetron, dexamethasone (FPD) regimen was 150 mg IV fosaprepitant, 0.25 mg IV palonosetron, and 12 mg IV dexamethasone before chemotherapy on day 1, and 4 mg dexamethasone PO BID, before chemotherapy days 2 and 3.
RESULTS: 101 of the 120 patients were evaluable. In 51 patients who received the OPD regimen, the complete response (CR; no emesis, no rescue medication) rate was 88% for the acute period (24 h after chemotherapy), 76% for the delayed period (days 2-5), and 76% for the overall period (0-120 h). In 50 patients who received the FPD regimen, the CR was 84% acute, 74% delayed, and 74% overall (𝑃 > .01 for all periods). Patients with no nausea (0, on a scale 0-10, visual analogue scale) were: OPD: 86% acute, 71% delayed, 71% overall; FPD: 78% acute, 40% delayed, 40% overall (𝑃 > .01 for acute; 𝑃 < .01 for delayed and overall) There were no grade 3 or 4 toxicities.
CONCLUSIONS: CR was similar for OPD and FPD; nausea in the delayed and overall periods was signifcantly improved with OPD compared with FPD (𝑃 < .01). ©2016 Frontline Medical Communications.

Entities:  

Keywords:  antiemetic; chemotherapy; emesis; fosaprepitant; nausea; olanzapine; radiotherapy

Year:  2016        PMID: 27152512     DOI: 10.12788/jcso.0245

Source DB:  PubMed          Journal:  J Community Support Oncol        ISSN: 2330-7749


  17 in total

Review 1.  2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting.

Authors:  Christina H Ruhlmann; Franziska Jahn; Karin Jordan; Kristopher Dennis; Ernesto Maranzano; Alexander Molassiotis; Fausto Roila; Petra Feyer
Journal:  Support Care Cancer       Date:  2016-09-13       Impact factor: 3.603

2.  Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial.

Authors:  Jun Cao; Quchang Ouyang; Shusen Wang; Joseph Ragaz; Xiaojia Wang; Yuee Teng; Biyun Wang; Zhonghua Wang; Jian Zhang; Leiping Wang; Jiong Wu; Zhimin Shao; Xichun Hu
Journal:  Invest New Drugs       Date:  2020-02-08       Impact factor: 3.850

Review 3.  Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis.

Authors:  Ting Yang; Qianxin Liu; Min Lu; Lingyue Ma; Ying Zhou; Yimin Cui
Journal:  Br J Clin Pharmacol       Date:  2017-03-23       Impact factor: 4.335

4.  A pooled analysis of adding olanzapine to guideline-recommended antiemetic therapy for breast cancer patients treated with an anthracycline and cyclophosphamide in prospective and retrospective studies.

Authors:  Bo-Ya Xiao; Tong Su; Yu-Jia Huang; Guo-He Lin; Zhao-Bo Liu; Yun-Xiang Tang; Bi-Cheng Wang
Journal:  Support Care Cancer       Date:  2021-11-13       Impact factor: 3.603

5.  Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors.

Authors:  Sonam Puri; Kelly A Hyland; Kristine Crowe Weiss; Gillian C Bell; Jhanelle E Gray; Richard Kim; Hui-Yi Lin; Aasha I Hoogland; Brian D Gonzalez; Ashley M Nelson; Anita Y Kinney; Stacy M Fischer; Daneng Li; Paul B Jacobsen; Howard L McLeod; Heather S L Jim
Journal:  Support Care Cancer       Date:  2018-03-15       Impact factor: 3.603

6.  Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.

Authors:  Zhonghan Zhang; Yaxiong Zhang; Gang Chen; Shaodong Hong; Yunpeng Yang; Wenfeng Fang; Fan Luo; Xi Chen; Yuxiang Ma; Yuanyuan Zhao; Jianhua Zhan; Cong Xue; Xue Hou; Ting Zhou; Shuxiang Ma; Fangfang Gao; Yan Huang; Likun Chen; Ningning Zhou; Hongyun Zhao; Li Zhang
Journal:  Oncologist       Date:  2018-01-12

7.  Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis.

Authors:  Abdullah A Alhifany; Ali McBride; Abdulaali R Almutairi; Ejaz Cheema; Alaa Shahbar; Yasser Alatawi; Adnan S Alharbi; Hani Babiker; Karen MacDonald; Matti Aapro; Ivo Abraham
Journal:  Support Care Cancer       Date:  2019-12-10       Impact factor: 3.603

8.  Radioprotective effect of olanzapine as an anti-psychotic drug against genotoxicity and apoptosis induced by ionizing radiation on human lymphocytes.

Authors:  Mohammad Asghari; Zahra Shaghaghi; Soghra Farzipour; Arash Ghasemi; Seyed Jalal Hosseinimehr
Journal:  Mol Biol Rep       Date:  2019-08-12       Impact factor: 2.316

9.  Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials.

Authors:  Senri Yamamoto; Hirotoshi Iihara; Ryuji Uozumi; Hitoshi Kawazoe; Kazuki Tanaka; Yukiyoshi Fujita; Masakazu Abe; Hisao Imai; Masato Karayama; Yoh Hayasaki; Chiemi Hirose; Takafumi Suda; Kazuto Nakamura; Akio Suzuki; Yasushi Ohno; Ken-Ichirou Morishige; Naoki Inui
Journal:  BMC Cancer       Date:  2021-07-19       Impact factor: 4.430

Review 10.  Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.

Authors:  Anna Sutherland; Katrien Naessens; Emma Plugge; Lynda Ware; Karen Head; Martin J Burton; Bee Wee
Journal:  Cochrane Database Syst Rev       Date:  2018-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.